Novo May Add Hundreds to R&D Staff for Obesity Medicines
This article is for subscribers only.
Novo Nordisk A/S, which this month moved a step closer to U.S. approval of its first weight-loss medicine, may add hundreds of people in research and development to develop a range of therapies to fight obesity.
Novo Nordisk, the world’s biggest insulin maker, is hiring the “most eminent people” in obesity, Chief Science Officer Mads Krogsgaard Thomsen said in an interview. The Bagsvaerd, Denmark-based company will seek collaborations with universities and biotechnology firms to get new ideas for therapies it can then develop in-house, he said.